PYRUKYND Trademark

Trademark Overview

On Friday, June 11, 2021, a trademark application was filed for PYRUKYND with the United States Patent and Trademark Office. The USPTO has given the PYRUKYND trademark a serial number of 90768907. The federal status of this trademark filing is FIFTH EXTENSION - GRANTED as of Monday, June 3, 2024. This trademark is owned by Agios Pharmaceuticals, Inc.. The PYRUKYND trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations, namely, for the activation of PKR (pyruvate kinase R), for the activation of PKM2 (pyruvate kinase isozyme M2), and for the prevention and treatment of blood disorders, sickle cell disease, pyruvate kinase deficiency (PKD), beta thalassemia and alpha thalassemia, genetically defined diseases affecting red blood cells, hereditary spherocytosis, hereditary elliptocytosis, dyserythropoiesis, hemolytic anemia, and other anemias
pyrukynd

General Information

Serial Number90768907
Word MarkPYRUKYND
Filing DateFriday, June 11, 2021
Status734 - FIFTH EXTENSION - GRANTED
Status DateMonday, June 3, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing3 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s)
Published for Opposition DateTuesday, October 12, 2021

Trademark Statements

Description of MarkThe mark consists of four check mark designs joined at their bottoms, forming a stylized starburst shape with two purple triangles in the center; the check mark designs are colored turquoise, chartreuse, fuchsia and white, moving clockwise from the upper right of the design. The word "PYRUKYND" appears in stylized white lettering to the lower right of the starburst design, with the entire mark appearing upon a purple background.
Goods and ServicesPharmaceutical preparations, namely, for the activation of PKR (pyruvate kinase R), for the activation of PKM2 (pyruvate kinase isozyme M2), and for the prevention and treatment of blood disorders, sickle cell disease, pyruvate kinase deficiency (PKD), beta thalassemia and alpha thalassemia, genetically defined diseases affecting red blood cells, hereditary spherocytosis, hereditary elliptocytosis, dyserythropoiesis, hemolytic anemia, and other anemias
Indication of Colors claimedThe color(s) purple, fuchsia, chartreuse, turquoise and white is/are claimed as a feature of the mark.

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, August 31, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameAgios Pharmaceuticals, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressCambridge, MA 021394169
Party NameAgios Pharmaceuticals, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressCambridge, MA 021394169

Trademark Events

Event DateEvent Description
Tuesday, June 15, 2021NEW APPLICATION ENTERED
Thursday, July 1, 2021TEAS CHANGE OF OWNER ADDRESS RECEIVED
Thursday, July 1, 2021TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, July 1, 2021APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Tuesday, August 31, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, September 1, 2021NOTICE OF DESIGN SEARCH CODE E-MAILED
Wednesday, September 8, 2021ASSIGNED TO EXAMINER
Wednesday, September 8, 2021EXAMINERS AMENDMENT -WRITTEN
Wednesday, September 8, 2021EXAMINERS AMENDMENT E-MAILED
Wednesday, September 8, 2021NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Wednesday, September 8, 2021EXAMINER'S AMENDMENT ENTERED
Wednesday, September 8, 2021EXAMINERS AMENDMENT -WRITTEN
Wednesday, September 8, 2021EXAMINERS AMENDMENT E-MAILED
Wednesday, September 8, 2021NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Wednesday, September 8, 2021EXAMINER'S AMENDMENT ENTERED
Wednesday, September 8, 2021APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, September 22, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, October 12, 2021PUBLISHED FOR OPPOSITION
Tuesday, October 12, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, December 7, 2021NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Wednesday, February 9, 2022TEAS CHANGE OF OWNER ADDRESS RECEIVED
Wednesday, February 9, 2022TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Wednesday, February 9, 2022ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Wednesday, February 9, 2022TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, February 9, 2022APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Thursday, June 2, 2022SOU TEAS EXTENSION RECEIVED
Thursday, June 2, 2022SOU EXTENSION 1 FILED
Thursday, June 2, 2022SOU EXTENSION 1 GRANTED
Saturday, June 4, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, December 2, 2022SOU TEAS EXTENSION RECEIVED
Friday, December 2, 2022SOU EXTENSION 2 FILED
Friday, December 2, 2022SOU EXTENSION 2 GRANTED
Tuesday, December 6, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, June 5, 2023SOU TEAS EXTENSION RECEIVED
Monday, June 5, 2023SOU EXTENSION 3 FILED
Monday, June 5, 2023SOU EXTENSION 3 GRANTED
Wednesday, June 7, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, December 4, 2023SOU TEAS EXTENSION RECEIVED
Monday, December 4, 2023SOU EXTENSION 4 FILED
Monday, December 4, 2023SOU EXTENSION 4 GRANTED
Wednesday, December 6, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, June 3, 2024SOU TEAS EXTENSION RECEIVED
Monday, June 3, 2024SOU EXTENSION 5 FILED
Monday, June 3, 2024SOU EXTENSION 5 GRANTED
Thursday, June 13, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED

Related Keywords

pyrukynd pyruvate kinase thalassemia blood hereditary activation cells diseases defined spherocytosis